Tolerance of Two Forms of Vitamin C in Acid-sensitive Adults
A Randomized, Double-blind, Crossover Study Comparing the Tolerance of Two Forms of Vitamin C in Acid Sensitive Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5R8
- KGK Synergize, Inc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy as determined by laboratory results and medical history
- Females not of child bearing potential
- Self-reported sensitivity to acidic foods
- Agrees to consume a low vitamin C diet
Exclusion Criteria:
- Pregnant, breastfeeding, or planning to become pregnant during the trial
- Use of medications known to interact with vitamin C or cause epigastric effects
- Use of supplements containing containing vitamin C
- Duodenal ulcer or gastric ulcer, gastritis, hiatus hernia, or gastroesophageal reflux disease (GERD) within past 3 months
- Use of antacids and/or acid suppressors within 4 weeks of randomization
- History of irritable bowel syndrome and related disorders
- Alcohol use > 2 standard alcoholic drinks per day; alcohol or drug abuse within the past year
- History of cardiac disease within the past 6 months
- History of or current diagnosis of cancer
- Uncontrolled hypertension
- Unstable renal and/or liver disease
- History of kidney stones
- Unstable psychiatric disorder
- History of or current immunocompromise
- History of hemoglobinopathies
- Participation in another clinical research trial <30 days
- Abnormal liver function
- Serum creatinine > 1.5 x upper limit of normal (ULN)
- Anemia of any etiology
- Uncontrolled and/or untreated thyroid disorder
- BMI ≥ 35 kg/m2
- Unstable medications <30 days
- Allergy or sensitivity to test article ingredients
- Cognitively impaired and/or unable to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Calcium ascorbate -> ascorbic acid
|
|
|
Experimental: Ascorbic acid -> calcium ascorbate
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change from Baseline Gastrointestinal Symptom Rating Scale at 5 and 10 days
Time Frame: 0, 5 and 10 days
|
0, 5 and 10 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 07EAHT
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.